Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials
• Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed....
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Duffaud, F. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study - Hamzah, N. ELSEVIER, 2018, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:51 ; year:2015 ; number:17 ; pages:2615-2623 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ejca.2015.08.002 |
|---|
| Katalog-ID: |
ELV013275275 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV013275275 | ||
| 003 | DE-627 | ||
| 005 | 20230623104315.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2015.08.002 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015016000026.pica |
| 035 | |a (DE-627)ELV013275275 | ||
| 035 | |a (ELSEVIER)S0959-8049(15)00777-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.52 |2 bkl | ||
| 100 | 1 | |a Duffaud, F. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials |
| 264 | 1 | |c 2015 | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed. • No association was found between the occurrence of HTN and outcome. | ||
| 650 | 7 | |a Hypertension |2 Elsevier | |
| 650 | 7 | |a Biomarker |2 Elsevier | |
| 650 | 7 | |a Sarcoma |2 Elsevier | |
| 650 | 7 | |a Pazopanib |2 Elsevier | |
| 700 | 1 | |a Sleijfer, S. |4 oth | |
| 700 | 1 | |a Litière, S. |4 oth | |
| 700 | 1 | |a Ray-Coquard, I. |4 oth | |
| 700 | 1 | |a Le Cesne, A. |4 oth | |
| 700 | 1 | |a Papai, Z. |4 oth | |
| 700 | 1 | |a Judson, I. |4 oth | |
| 700 | 1 | |a Schöffski, P. |4 oth | |
| 700 | 1 | |a Chawla, S.P. |4 oth | |
| 700 | 1 | |a Dewji, R. |4 oth | |
| 700 | 1 | |a Marreaud, S. |4 oth | |
| 700 | 1 | |a Verweij, J. |4 oth | |
| 700 | 1 | |a van der Graaf, W.T. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Hamzah, N. ELSEVIER |t The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |d 2018 |g Amsterdam [u.a.] |w (DE-627)ELV000241849 |
| 773 | 1 | 8 | |g volume:51 |g year:2015 |g number:17 |g pages:2615-2623 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2015.08.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 51 |j 2015 |e 17 |h 2615-2623 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
f d fd |
|---|---|
| matchkey_str |
duffaudfsleijferslitiresraycoquardileces:2015----:yetnintaaoetaboakrffiaynaoaitetdainsihdacdoaioyisftsusroartopcietdbsdnuoenraiai |
| hierarchy_sort_str |
2015 |
| bklnumber |
44.52 |
| publishDate |
2015 |
| allfields |
10.1016/j.ejca.2015.08.002 doi GBVA2015016000026.pica (DE-627)ELV013275275 (ELSEVIER)S0959-8049(15)00777-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.52 bkl Duffaud, F. verfasserin aut Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials 2015 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed. • No association was found between the occurrence of HTN and outcome. Hypertension Elsevier Biomarker Elsevier Sarcoma Elsevier Pazopanib Elsevier Sleijfer, S. oth Litière, S. oth Ray-Coquard, I. oth Le Cesne, A. oth Papai, Z. oth Judson, I. oth Schöffski, P. oth Chawla, S.P. oth Dewji, R. oth Marreaud, S. oth Verweij, J. oth van der Graaf, W.T. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:51 year:2015 number:17 pages:2615-2623 extent:9 https://doi.org/10.1016/j.ejca.2015.08.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 51 2015 17 2615-2623 9 045F 610 |
| spelling |
10.1016/j.ejca.2015.08.002 doi GBVA2015016000026.pica (DE-627)ELV013275275 (ELSEVIER)S0959-8049(15)00777-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.52 bkl Duffaud, F. verfasserin aut Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials 2015 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed. • No association was found between the occurrence of HTN and outcome. Hypertension Elsevier Biomarker Elsevier Sarcoma Elsevier Pazopanib Elsevier Sleijfer, S. oth Litière, S. oth Ray-Coquard, I. oth Le Cesne, A. oth Papai, Z. oth Judson, I. oth Schöffski, P. oth Chawla, S.P. oth Dewji, R. oth Marreaud, S. oth Verweij, J. oth van der Graaf, W.T. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:51 year:2015 number:17 pages:2615-2623 extent:9 https://doi.org/10.1016/j.ejca.2015.08.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 51 2015 17 2615-2623 9 045F 610 |
| allfields_unstemmed |
10.1016/j.ejca.2015.08.002 doi GBVA2015016000026.pica (DE-627)ELV013275275 (ELSEVIER)S0959-8049(15)00777-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.52 bkl Duffaud, F. verfasserin aut Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials 2015 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed. • No association was found between the occurrence of HTN and outcome. Hypertension Elsevier Biomarker Elsevier Sarcoma Elsevier Pazopanib Elsevier Sleijfer, S. oth Litière, S. oth Ray-Coquard, I. oth Le Cesne, A. oth Papai, Z. oth Judson, I. oth Schöffski, P. oth Chawla, S.P. oth Dewji, R. oth Marreaud, S. oth Verweij, J. oth van der Graaf, W.T. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:51 year:2015 number:17 pages:2615-2623 extent:9 https://doi.org/10.1016/j.ejca.2015.08.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 51 2015 17 2615-2623 9 045F 610 |
| allfieldsGer |
10.1016/j.ejca.2015.08.002 doi GBVA2015016000026.pica (DE-627)ELV013275275 (ELSEVIER)S0959-8049(15)00777-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.52 bkl Duffaud, F. verfasserin aut Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials 2015 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed. • No association was found between the occurrence of HTN and outcome. Hypertension Elsevier Biomarker Elsevier Sarcoma Elsevier Pazopanib Elsevier Sleijfer, S. oth Litière, S. oth Ray-Coquard, I. oth Le Cesne, A. oth Papai, Z. oth Judson, I. oth Schöffski, P. oth Chawla, S.P. oth Dewji, R. oth Marreaud, S. oth Verweij, J. oth van der Graaf, W.T. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:51 year:2015 number:17 pages:2615-2623 extent:9 https://doi.org/10.1016/j.ejca.2015.08.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 51 2015 17 2615-2623 9 045F 610 |
| allfieldsSound |
10.1016/j.ejca.2015.08.002 doi GBVA2015016000026.pica (DE-627)ELV013275275 (ELSEVIER)S0959-8049(15)00777-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.52 bkl Duffaud, F. verfasserin aut Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials 2015 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed. • No association was found between the occurrence of HTN and outcome. Hypertension Elsevier Biomarker Elsevier Sarcoma Elsevier Pazopanib Elsevier Sleijfer, S. oth Litière, S. oth Ray-Coquard, I. oth Le Cesne, A. oth Papai, Z. oth Judson, I. oth Schöffski, P. oth Chawla, S.P. oth Dewji, R. oth Marreaud, S. oth Verweij, J. oth van der Graaf, W.T. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:51 year:2015 number:17 pages:2615-2623 extent:9 https://doi.org/10.1016/j.ejca.2015.08.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 51 2015 17 2615-2623 9 045F 610 |
| language |
English |
| source |
Enthalten in The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study Amsterdam [u.a.] volume:51 year:2015 number:17 pages:2615-2623 extent:9 |
| sourceStr |
Enthalten in The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study Amsterdam [u.a.] volume:51 year:2015 number:17 pages:2615-2623 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Therapie |
| institution |
findex.gbv.de |
| topic_facet |
Hypertension Biomarker Sarcoma Pazopanib |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| authorswithroles_txt_mv |
Duffaud, F. @@aut@@ Sleijfer, S. @@oth@@ Litière, S. @@oth@@ Ray-Coquard, I. @@oth@@ Le Cesne, A. @@oth@@ Papai, Z. @@oth@@ Judson, I. @@oth@@ Schöffski, P. @@oth@@ Chawla, S.P. @@oth@@ Dewji, R. @@oth@@ Marreaud, S. @@oth@@ Verweij, J. @@oth@@ van der Graaf, W.T. @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000241849 |
| dewey-sort |
3610 |
| id |
ELV013275275 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV013275275</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623104315.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejca.2015.08.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015016000026.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV013275275</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0959-8049(15)00777-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Duffaud, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed. • No association was found between the occurrence of HTN and outcome.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hypertension</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biomarker</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sarcoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pazopanib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sleijfer, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Litière, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ray-Coquard, I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Le Cesne, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Papai, Z.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Judson, I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schöffski, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chawla, S.P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dewji, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marreaud, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verweij, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Graaf, W.T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Hamzah, N. ELSEVIER</subfield><subfield code="t">The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000241849</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:51</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:17</subfield><subfield code="g">pages:2615-2623</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejca.2015.08.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">51</subfield><subfield code="j">2015</subfield><subfield code="e">17</subfield><subfield code="h">2615-2623</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Duffaud, F. |
| spellingShingle |
Duffaud, F. ddc 610 bkl 44.52 Elsevier Hypertension Elsevier Biomarker Elsevier Sarcoma Elsevier Pazopanib Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials |
| authorStr |
Duffaud, F. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000241849 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.52 bkl Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials Hypertension Elsevier Biomarker Elsevier Sarcoma Elsevier Pazopanib Elsevier |
| topic |
ddc 610 bkl 44.52 Elsevier Hypertension Elsevier Biomarker Elsevier Sarcoma Elsevier Pazopanib |
| topic_unstemmed |
ddc 610 bkl 44.52 Elsevier Hypertension Elsevier Biomarker Elsevier Sarcoma Elsevier Pazopanib |
| topic_browse |
ddc 610 bkl 44.52 Elsevier Hypertension Elsevier Biomarker Elsevier Sarcoma Elsevier Pazopanib |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s s ss s l sl i r c irc c a l ca cal z p zp i j ij p s ps s c sc r d rd s m sm j v jv d g w v dgw dgwv |
| hierarchy_parent_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| hierarchy_parent_id |
ELV000241849 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000241849 |
| title |
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials |
| ctrlnum |
(DE-627)ELV013275275 (ELSEVIER)S0959-8049(15)00777-7 |
| title_full |
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials |
| author_sort |
Duffaud, F. |
| journal |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| journalStr |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
2615 |
| author_browse |
Duffaud, F. |
| container_volume |
51 |
| physical |
9 |
| class |
610 610 DE-600 610 VZ 44.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Duffaud, F. |
| doi_str_mv |
10.1016/j.ejca.2015.08.002 |
| dewey-full |
610 |
| title_sort |
hypertension (htn) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. a retrospective study based on european organisation for research and treatment of cancer (eortc) 62043 and 62072 trials |
| title_auth |
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials |
| abstract |
• Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed. • No association was found between the occurrence of HTN and outcome. |
| abstractGer |
• Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed. • No association was found between the occurrence of HTN and outcome. |
| abstract_unstemmed |
• Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed. • No association was found between the occurrence of HTN and outcome. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
17 |
| title_short |
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials |
| url |
https://doi.org/10.1016/j.ejca.2015.08.002 |
| remote_bool |
true |
| author2 |
Sleijfer, S. Litière, S. Ray-Coquard, I. Le Cesne, A. Papai, Z. Judson, I. Schöffski, P. Chawla, S.P. Dewji, R. Marreaud, S. Verweij, J. van der Graaf, W.T. |
| author2Str |
Sleijfer, S. Litière, S. Ray-Coquard, I. Le Cesne, A. Papai, Z. Judson, I. Schöffski, P. Chawla, S.P. Dewji, R. Marreaud, S. Verweij, J. van der Graaf, W.T. |
| ppnlink |
ELV000241849 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ejca.2015.08.002 |
| up_date |
2024-07-06T18:29:27.638Z |
| _version_ |
1803855402253680640 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV013275275</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623104315.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejca.2015.08.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015016000026.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV013275275</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0959-8049(15)00777-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Duffaud, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed. • No association was found between the occurrence of HTN and outcome.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hypertension</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biomarker</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sarcoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pazopanib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sleijfer, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Litière, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ray-Coquard, I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Le Cesne, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Papai, Z.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Judson, I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schöffski, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chawla, S.P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dewji, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marreaud, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verweij, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Graaf, W.T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Hamzah, N. ELSEVIER</subfield><subfield code="t">The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000241849</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:51</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:17</subfield><subfield code="g">pages:2615-2623</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejca.2015.08.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">51</subfield><subfield code="j">2015</subfield><subfield code="e">17</subfield><subfield code="h">2615-2623</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.39896 |